[go: up one dir, main page]

PE20030726A1 - 4-feniltetrahidroisoquinolinas sustituidas, proceso para su preparacion y composiciones farmaceuticas que las contienen - Google Patents

4-feniltetrahidroisoquinolinas sustituidas, proceso para su preparacion y composiciones farmaceuticas que las contienen

Info

Publication number
PE20030726A1
PE20030726A1 PE2002001138A PE2002001138A PE20030726A1 PE 20030726 A1 PE20030726 A1 PE 20030726A1 PE 2002001138 A PE2002001138 A PE 2002001138A PE 2002001138 A PE2002001138 A PE 2002001138A PE 20030726 A1 PE20030726 A1 PE 20030726A1
Authority
PE
Peru
Prior art keywords
substituted
phenyltehydroisoquinolines
tetrahydroisoquinoli
nil
dichloro
Prior art date
Application number
PE2002001138A
Other languages
English (en)
Inventor
Armin Hofmeister
Uwe Heinelt
Hans-Jochen Lang
Klaus Wirth
Markus Bleich
Michael Gekle
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of PE20030726A1 publication Critical patent/PE20030726A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/16Central respiratory analeptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/18Aralkyl radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

SE REFIERE A DERIVADOS DE 4-FENILTETRAHIDROISOQUINOLINAS SUSTITUIDAS DE FORMULA I DONDE R1-R4 SON H, F, Cl, Br, I, CN, NO2, NH2, ENTRE OTROS; R5 ES H, CpH2p+1, COR20; p ES 1-8; R6 ES H, F, Cl, Br, I, OH, ENTRE OTROS; R7-R9 SON -Ov-SOw-R23; v ES 0-1; w ES 1-2; R23 ES CnnH2nn+1, CmmH2mm-1; nn ES 1-8; mm ES 3-8. SON COMPUESTOS PREFERIDOS N-[4-(6,8-DICLORO-2-METIL-1,2,3,4-TETRAHIDROISOQUINOLI-4-NIL)-FENIL]-ACETAMIDA, 4-(6,8-DICLORO-2-METIL-1,2,3,4-TETRAHIDROISOQUINOLI-4-NIL)--BENCENOSULFONAMIDA, 3-(6,8-DICLORO-2-METIL-1,2,3,4-TETRAHIDROISOQUINOLI-4-NIL)-BENCENOSULFONAMIDA, ENTRE OTROS. LOS COMPUESTOS MENCIONADOS SON INHIBIDORES DEL ANTITRANSPORTADOR CELULAR PROTONICO DE SODIO (INTERCAMBIO Na/H) Y SON UTILES PARA EL TRATAMIENTO DE HIPERTENSION, REDUCIR LA ISQUEMIA DEL SISTEMA NERVIOSO CENTRAL
PE2002001138A 2001-12-05 2002-11-26 4-feniltetrahidroisoquinolinas sustituidas, proceso para su preparacion y composiciones farmaceuticas que las contienen PE20030726A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10159714 2001-12-05

Publications (1)

Publication Number Publication Date
PE20030726A1 true PE20030726A1 (es) 2003-09-30

Family

ID=7708117

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002001138A PE20030726A1 (es) 2001-12-05 2002-11-26 4-feniltetrahidroisoquinolinas sustituidas, proceso para su preparacion y composiciones farmaceuticas que las contienen

Country Status (33)

Country Link
EP (1) EP1453810B1 (es)
JP (1) JP4510457B2 (es)
KR (1) KR20050044724A (es)
CN (1) CN100497314C (es)
AR (1) AR037620A1 (es)
AT (1) ATE425968T1 (es)
AU (1) AU2002356689B2 (es)
BR (1) BR0214753A (es)
CA (1) CA2469385A1 (es)
CO (1) CO5580748A2 (es)
DE (1) DE50213372D1 (es)
DK (1) DK1453810T3 (es)
EC (1) ECSP045138A (es)
ES (1) ES2324528T3 (es)
HR (1) HRP20040507A2 (es)
HU (1) HUP0600854A2 (es)
IL (1) IL162316A0 (es)
MA (1) MA27147A1 (es)
MX (1) MXPA04005343A (es)
MY (1) MY157371A (es)
NO (1) NO326650B1 (es)
NZ (1) NZ533322A (es)
OA (1) OA12740A (es)
PE (1) PE20030726A1 (es)
PL (1) PL369313A1 (es)
PT (1) PT1453810E (es)
RS (1) RS48004A (es)
RU (1) RU2298003C2 (es)
TN (1) TNSN04100A1 (es)
TW (1) TWI281860B (es)
UA (1) UA77042C2 (es)
WO (1) WO2003048129A1 (es)
ZA (1) ZA200403711B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10312963A1 (de) * 2003-03-24 2004-10-07 Aventis Pharma Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
TW200526626A (en) 2003-09-13 2005-08-16 Astrazeneca Ab Chemical compounds
DE102004046492A1 (de) 2004-09-23 2006-03-30 Sanofi-Aventis Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
US20060111393A1 (en) * 2004-11-22 2006-05-25 Molino Bruce F 4-Phenyl substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
DE102005001411A1 (de) * 2005-01-12 2006-07-27 Sanofi-Aventis Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
US8399489B2 (en) 2005-02-18 2013-03-19 Astrazeneca Ab Antibacterial piperdine derivatives
EP1861393A2 (en) * 2005-03-04 2007-12-05 AstraZeneca AB Pyrrole derivatives as dna gyrase and topoisomerase inhibitors
DE102005044817A1 (de) * 2005-09-20 2007-03-22 Sanofi-Aventis Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
DE102006012545A1 (de) 2006-03-18 2007-09-27 Sanofi-Aventis Substituierte 2-Amino-4-phenyl-dihydrochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
EP2384318B1 (en) 2008-12-31 2017-11-15 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US10543207B2 (en) 2008-12-31 2020-01-28 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2018129556A1 (en) * 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
KR20120034644A (ko) 2009-05-12 2012-04-12 알바니 몰레큘라 리써치, 인크. 아릴, 헤테로아릴, 및 헤테로사이클 치환된 테트라하이드로이소퀴놀린 및 이의 용도
MX363056B (es) * 2012-08-21 2019-03-06 Ardelyx Inc Compuestos y metodos para inhibir al antipuerto mediado por nhe en el tratamiento de trastornos asociados con la retencion de fluidos o la sobrecarga de sal y trastornos del tracto gastrointestinal.
AU2014250956B2 (en) 2013-04-12 2019-04-04 Ardelyx, Inc. NHE3-binding compounds and methods for inhibiting phosphate transport
CN103788084A (zh) * 2014-03-02 2014-05-14 湖南华腾制药有限公司 四氢异喹啉衍生物及其合成方法
TWI666206B (zh) * 2014-07-25 2019-07-21 日商大正製藥股份有限公司 以雜芳基取代之苯基四氫異喹啉化合物
JP6903923B2 (ja) * 2016-01-22 2021-07-14 大正製薬株式会社 ヘテロアリールで置換されたフェニルテトラヒドロイソキノリン化合物を有効成分として含有する医薬
WO2018129557A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Inhibitors of nhe-mediated antiport
WO2018129552A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds useful for treating gastrointestinal tract disorders
AU2021401102B2 (en) * 2020-12-18 2024-03-07 Jiangxi Jemincare Group Co., Ltd Benzoheterocycle substituted tetrahydroisoquinoline compound

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19951702A1 (de) * 1999-10-27 2001-05-03 Aventis Pharma Gmbh Verwendung von 2-Amino-3,4-dihydro-chinazolinen zur Herstellung eines Medikaments zur Behandlung oder Prophylaxe von durch ischämischen Zuständen bewirkten Krankheiten
EP1246805A1 (en) * 1999-11-03 2002-10-09 Albany Molecular Research, Inc. 4-phenyl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
JP4907818B2 (ja) * 1999-11-03 2012-04-04 エーエムアール テクノロジー インコーポレイテッド アリールおよびヘテロアリール置換テトラヒドロイソキノリン、ならびにノルエピネフリン、ドーパミンおよびセロトニンの再取り込みを阻止するためのそれらの使用
EP1113007A1 (en) * 1999-12-24 2001-07-04 Pfizer Inc. Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
DE10019062A1 (de) * 2000-04-18 2001-10-25 Merck Patent Gmbh 2-Guanidino-4-aryl-chinazoline als NHE-3 Inhibitoren

Also Published As

Publication number Publication date
DE50213372D1 (de) 2009-04-30
MXPA04005343A (es) 2004-09-27
ATE425968T1 (de) 2009-04-15
KR20050044724A (ko) 2005-05-12
TW200306190A (en) 2003-11-16
EP1453810B1 (de) 2009-03-18
HUP0600854A2 (en) 2007-02-28
TNSN04100A1 (en) 2006-06-01
WO2003048129A1 (de) 2003-06-12
HK1072597A1 (zh) 2005-09-02
ES2324528T3 (es) 2009-08-10
JP4510457B2 (ja) 2010-07-21
HRP20040507A2 (en) 2005-08-31
RU2298003C2 (ru) 2007-04-27
RU2004120295A (ru) 2006-01-10
ZA200403711B (en) 2005-06-09
DK1453810T3 (da) 2009-07-20
IL162316A0 (en) 2005-11-20
NZ533322A (en) 2006-02-24
ECSP045138A (es) 2004-08-27
AU2002356689A1 (en) 2003-06-17
BR0214753A (pt) 2004-12-14
CA2469385A1 (en) 2003-06-12
AR037620A1 (es) 2004-11-17
JP2005515205A (ja) 2005-05-26
NO326650B1 (no) 2009-01-26
EP1453810A1 (de) 2004-09-08
CN1617856A (zh) 2005-05-18
UA77042C2 (en) 2006-10-16
MA27147A1 (fr) 2005-01-03
OA12740A (en) 2006-06-30
RS48004A (sr) 2006-10-27
PL369313A1 (en) 2005-04-18
PT1453810E (pt) 2009-05-27
MY157371A (en) 2016-06-15
NO20042158L (no) 2004-08-27
AU2002356689B2 (en) 2008-05-15
TWI281860B (en) 2007-06-01
CO5580748A2 (es) 2005-11-30
CN100497314C (zh) 2009-06-10

Similar Documents

Publication Publication Date Title
PE20030726A1 (es) 4-feniltetrahidroisoquinolinas sustituidas, proceso para su preparacion y composiciones farmaceuticas que las contienen
PE20010130A1 (es) Derivados de 3(5)-amino-pirazol y procedimiento para su preparacion
DK2314582T3 (da) Heterocykliske forbindelser som antivirusmidler
PE20050131A1 (es) Derivados de benzoimidazol como agentes antiproliferativos
PE20021088A1 (es) Amidas de acidos antranilicos, procedimiento para su preparacion asi como preparados farmaceuticos que las contienen
AR036233A1 (es) Un compuesto derivado de indol, su uso, procesos para prepararlo y una composicion farmaceutica que lo comprende
NO20035524D0 (no) 4'-substituerte nukleosider
ECSP045469A (es) El uso de cianopirrolidinas sustituidas y preparaciones de combinacion que las contienen para tratar hiperlipidemia y enfermedades asociadas
PE20040698A1 (es) Derivados de isoindolina
AR037096A1 (es) Compuestos de benzimidazol sustituido,composicion farmacologica que los comprende y uso de los mismos para la preparacion de una droga
SE0201194D0 (sv) New compounds
EA200600694A1 (ru) Дисульфидные, сульфидные, сульфоксидные и сульфоновые производные циклических сахаров и их применение
ATE277897T1 (de) Aminobenzophenone als inhibitoren von il-1beta und tnf-alpha
AR007997A1 (es) Un derivado de distamicina sustituida con acriloilo, sus utilizaciones, un procedimiento para producirlo y una composicion farmaceutica que lo comprende.
PE20030707A1 (es) Agonistas muscarinicos
NO930143L (no) Piperidinforbindelser, deres fremstilling og bruk
UY27413A1 (es) Agonistas de la oxitocina
PE20020845A1 (es) Derivados de o -amino-n-hidroxi-acetamida
ECSP22082217A (es) Derivados de n-heteroarilalquil-2-(heterociclil y heterociclilmetil)acetamida
PT1430034E (pt) Derivados de alquilaminopiridazinona substituida processo para sua preparacao e composicoes farmaceuticas que os contem
PE20020339A1 (es) Derivados de pirrolidin como inhibidores de las metaloproteasas
AR031720A1 (es) Benzimidazoles n-alcoxialquil sustituidos, proceso para su preparacion, composiciones, y uso de estos compuestos para preparar composiciones antiparasitarias
PE20040205A1 (es) Derivados de azepano como inhibidores de la quinasa akt1
ES8602761A1 (es) Un procedimiento para preparar un derivado de primidona
PE20041060A1 (es) COMBINACION DE FENILCARBOXAMIDAS Y BLOQUEADORES DEL CANAL DE Ikr

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed